American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

$1.38 -4.83% NASDAQ: PACB · 15-min delayed

MENLO PARK, California
Public · NASDAQ: PACB
485 employees

Visit website Follow

$450.4MMarket cap

$78.6MRevenue · FY2018

-$546.4MNet income

485Employees

PACBNASDAQ

2010IPO

About PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: PACB
Employees: 485
IPO date: Oct 27, 2010
Headquarters: 1305 O'BRIEN DRIVE
MENLO PARK, California 94025
Phone: 650-521-8000
Industry: Medical Devices
Website: Visit site

Registry IDs

Ticker: PACB Nasdaq
SEC CIK: 1299130
LEI: 529900F1BWRE1M0KZN89
EIN: 161590339
SIC: 3826 LABORATORY ANALYTICAL INSTRUMENTS

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow PACIFIC BIOSCIENCES OF CALIFORNIA, INC. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2018: $78.6M
Net income: -$546.4M
Total assets: $784.1M
Market cap: $450.4M
Gross margin: 28.6%
Operating margin: -346.2%
Net margin: -341.5%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2021

FY2022

FY2023

FY2024

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $160.0M
Cost of revenue: $114.2M
Gross profit: $45.8M
Operating expenses: $599.6M
Operating income: -$553.9M
Income tax: $318.0K
Net income: -$546.4M
EPS (basic): $-1.82
EPS (diluted): $-1.82

Balance sheet

Total assets: $784.1M
Current assets: $375.1M
Total liabilities: $778.7M
Current liabilities: $72.8M
Shareholders’ equity: $5.3M

Cash flow

Operating cash flow: -$111.2M
Investing cash flow: $115.4M
Financing cash flow: $3.4M
Net cash flow: $7.7M

Statements via Polygon.io (SEC filings)

NASDAQ: PACB

$1.38 -4.83%

15-minute delayed · data by Polygon.io

Past year

$0.91 $2.67

52-week range

Market cap: $450.4M
EPS (diluted): $-1.82
Shares outstanding: 326.4M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Oct 27, 2010

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Reported a net loss of $546.4M in FY2018.
Revenue grew 23% from FY2021 to FY2025.
Gross margin of 28.6%, net margin -341.5%.
Trading 48% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.